The anti-human immunodeficiency virus drug rilpivirine decreases hepatic injury in a nutritional model of non-alcoholic fatty liver disease through activation of the IL6/IL22-STAT3-p53 axis
Martí-Rodrigo, A., Alegre, F., Polo, M., Moragrega, Á.B., Apostolova, N., Esplugues, J.V., Blas-García, A.Volume:
66
Year:
2017
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/s0168-8278(17)30599-8
File:
PDF, 58 KB
english, 2017